Skip to main content
. 2022 Dec 25;10(6):2204932. doi: 10.1002/advs.202204932

Figure 10.

Figure 10

MONs as cancer vaccine delivering antigens and/or adjuvants. a) Schematic illustration of the synthesis procedure of dendritic mesoporous organosilica spheres with controllable number (n) of shells (DMOHS‐nS) and double‐shelled dendritic mesoporous silica spheres (DMSHS‐2S). b) Transmission electron microscopy (TEM) images of DMON‐2S. c) Antitumor performance of various vaccine formulations. Reproduced with permission.[ 170 ] Copyright 2017, Wiley‐VCH. d) Schematic illustration of GDMON–P + OVA + CpG‐enhanced cancer immunotherapy. Reproduced with permission.[ 171 ] Copyright 2018, Elsevier Ltd. e) Schematic illustration of the simultaneous T‐cell activation and macrophage polarization for potent antitumor immunotherapy using the IO–LPMONs. f) IO–LPMONs inhibit tumor growth by causing T‐cell activation and M1 polarization in vivo. Reproduced with permission.[ 172 ] Copyright 2019, Wiley‐VCH.